FTO promotes tumor progression in gastric cancer (Zeng et al., 2024[331]; Wu et al., 2024[295]), bladder cancer (Wu et al., 2024[290]), colorectal cancer (Qiao et al., 2024[195]), hepatocellular carcinoma (Chen et al., 2024[15]; Jiang et al., 2024[105]), lung cancer (Gao et al., 2023[58]), cervical cancer (Wang et al., 2023[242]), and pancreatic cancer (Tan et al., 2022[233]; Wang et al., 2023[269]). Here, FTO is linked to hepatocellular carcinoma.